BDF
MRNA icon

Balasa Dinverno & Foltz’s Moderna MRNA Stock Holding History

Balasa Dinverno & Foltz’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$389K Buy
3,288
+63
+2% +$9.56K 0.02% 230
2022
Q2 		$461K Buy
3,225
+1,686
+110% +$241K 0.03% 209
2022
Q1 		$265K Sell
1,539
-320
-17% -$53.9K 0.02% 292
2021
Q4 		$472K Buy
1,859
+299
+19% +$87.4K 0.03% 211
2021
Q3 		$600K Buy
+1,560
New +$575K 0.04% 174

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Balasa Dinverno & Foltz's MRNA Position: Q3 2022 in Review

Balasa Dinverno & Foltz increased its Moderna (MRNA) stake by 2% in Q3 2022, buying an estimated $9.56K and bringing the position to 3,288 shares worth $389K. The position accounts for 0.02% of the portfolio, ranked #230.

Balasa Dinverno & Foltz first reported a position in MRNA in Q3 2021 and has held it in 5 quarters since. The position peaked at $600K in Q3 2021. 916 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Balasa Dinverno & Foltz held 3,288 shares of Moderna worth $389K as of Q3 2022.
  • Balasa Dinverno & Foltz bought 63 Moderna shares in Q3 2022, an estimated $9.56K.
  • Moderna made up 0.02% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #230 holding.
  • Balasa Dinverno & Foltz first reported a position in Moderna in Q3 2021 and has held it in 5 quarters since.
  • Balasa Dinverno & Foltz's Moderna position peaked at $600K in Q3 2021.
  • 916 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.